Skip to content
Home/Companies/Healthcare/HI-Bio

HI-Bio

Healthcare·US·Exited 2024·Held 3yr
Entry
2021
Hold
3yr
Exit
2024

Who owns HI-Bio?

HI-Bio was owned by Jeito Capital through Jeito I (2021 vintage) from 2021 to 2024, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Jeito Capital
Investor
Jeito Capital
Jeito I · 2021 · VC

Key facts

HQFrance
SectorHealthcare
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2024

More from Jeito I

Other portfolio companies in the same fund.

Corteria Pharmaceuticals
Corteria Pharmaceuticals
Active
BiotechFrance· 2023
Noema Pharma
Noema Pharma
Active
BiotechSwitzerland· 2023
Advesya
Advesya
Active
BiotechSpain· 2022
CatalYm
CatalYm
Active
BiotechGermany· 2022
CDR-Life
CDR-Life
Active
BiotechSwitzerland· 2022
EyeBio
Exited 2024
BiotechUS· 2022
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track HI-Bio

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy HI-Bio?

5 strategic and 115financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on HI-Bio.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue